Dupan-2 Levels in Pancreatic Cancer Patients with Lewis Negative Phenotype
Author Information
Author(s): S. Kawal, H. Oguchi, T. Kobayashi, M. Tokool, S. Furutal, M. Kanai, T. Homma
Primary Institution: Shinshu University School of Medicine
Hypothesis
Can Dupan-2 serve as a reliable marker for pancreatic cancer in patients who are negative for the Lewis blood group phenotype?
Conclusion
Dupan-2 levels are significantly elevated in pancreatic cancer patients who are negative for the Lewis blood group phenotype.
Supporting Evidence
- Dupan-2 levels were significantly higher in Lewis negative patients compared to Lewis positive patients.
- Among 39 CA19-9 negative patients, 13 were identified as Lewis negative.
- Serum levels of Dupan-2 were highly elevated in some Lewis negative patients.
Takeaway
This study found that Dupan-2 is a helpful marker for diagnosing pancreatic cancer, especially in patients who can't be diagnosed with the usual test, CA19-9.
Methodology
Serum levels of various tumor markers were measured in normal subjects and pancreatic cancer patients, with a focus on the Lewis blood group phenotype.
Limitations
The study may not account for all factors influencing tumor marker levels in pancreatic cancer.
Participant Demographics
The study included 207 normal subjects (97 men, 110 women) and 200 patients with pancreatic carcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website